OBJECTIVE: Lung cancer (LC) is one of the leading types of cancer in the structure of oncological morbidity and mortality among men and women in Moscow Region. The aim of our study was to calculate budget cost of LC treatment in Moscow Region.

METHODS: To estimate the annual costs of drug therapy in Moscow Region for patients with ICD C34 we have developed an analytical model, relying on data of Ministry of Health of the Moscow region, as well as literature sources.

RESULTS: There was estimated that five drugs take 75,01% of total cost of C34 treatment. The biggest part of budget takes Afatinib - 20,15%, then Gefitinib - 16,5%, Сrizotinib - 16,23%, Erlotinib – 11, 61% and Pembrolizumab – 10,52%. The other 134 INN – 24,99% of budget cost of LC treatment. We also analysed what number of people is provided with these drugs: Afatinib – 3,38% of all patients who receive drug therapy, Gefitinib – 4,64%, Krizotinib – 1,49%, Erlotinib – 3,98% and Pembrolizumab – 1,24%. The other 134 INN – 84,91% of patients with LC.

CONCLUSIONS: The structure of drug therapy costs in patients with LC in Moscow region demonstrates that for 13,95% patients Ministry of Health of the Moscow region spends 75,01% of budget costs.